| 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors AH Long, WM Haso, JF Shern, KM Wanhainen, M Murgai, M Ingaramo, ... Nature medicine 21 (6), 581-590, 2015 | 1583 | 2015 |
| Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade JJ Ishizuka, RT Manguso, CK Cheruiyot, K Bi, A Panda, A Iracheta-Vellve, ... Nature 565 (7737), 43-48, 2019 | 503 | 2019 |
| Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase AJ Walker, RG Majzner, L Zhang, K Wanhainen, AH Long, SM Nguyen, ... Molecular Therapy 25 (9), 2189-2201, 2017 | 317 | 2017 |
| Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for SarcomasMDSCs Limit GD2-CAR T-cell Therapy AH Long, SL Highfill, Y Cui, JP Smith, AJ Walker, S Ramakrishna, ... Cancer immunology research 4 (10), 869-880, 2016 | 294 | 2016 |
| Triggered release of therapeutic antibodies from nanodiamond complexes AH Smith, EM Robinson, XQ Zhang, EK Chow, Y Lin, E Osawa, J Xi, D Ho Nanoscale 3 (7), 2844-2848, 2011 | 117 | 2011 |
| Delayed cancer diagnoses and high mortality in children during the COVID‐19 pandemic YY Ding, S Ramakrishna, AH Long, CA Phillips, R Montiel‐Esparza, ... Pediatric blood & cancer 67 (9), 2020 | 83 | 2020 |
| Comparison against 186 canid whole-genome sequences reveals survival strategies of an ancient clonally transmissible canine tumor B Decker, BW Davis, M Rimbault, AH Long, E Karlins, V Jagannathan, ... Genome research 25 (11), 1646-1655, 2015 | 70 | 2015 |
| Lessons learned from a highly-active CD22-specific chimeric antigen receptor AH Long, WM Haso, RJ Orentas Oncoimmunology 2 (4), e23621, 2013 | 49 | 2013 |
| Checkpoint immunotherapy in pediatrics: here, gone, and back again AH Long, DA Morgenstern, A Leruste, F Bourdeaut, KL Davis American Society of Clinical Oncology Educational Book 42, 781-794, 2022 | 24 | 2022 |
| Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res.(2016) 4: 869–80. doi: 10.1158/2326-6066 AH Long, SL Highfill, Y Cui, JP Smith, AJ Walker, S Ramakrishna, ... CIR-15-0230, 0 | 20 | |
| Chimeric antigen receptor T-cell therapy against anaplastic lymphoma kinase (ALK) is limited by target antigen density and CAR surface expression RG Majzner, AJ Walker, M Murgai, L Zhang, AH Long, KM Wanhainen, ... Cancer Research 76 (14_Supplement), 2648-2648, 2016 | 4 | 2016 |
| Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors SL Highfill, AH Long, RJ Orentas, CL Mackall Journal for immunotherapy of cancer 1 (1), P265, 2013 | 3 | 2013 |
| Chimeric Antigen Receptors for Cancer: Progress and Challenges AH Long, DW Lee, CL Mackall Current stem cell reports 1, 187-196, 2015 | 2 | 2015 |
| Neutralization of murine myeloid suppressor cells enhances the efficacy of GD2-specific CAR T cells directed against human sarcoma in a xenograft model (VAC11P. 1010) S Highfill, J Smith, A Long, Y Cui, R Orentas, C Mackall The Journal of Immunology 192 (1_Supplement), 205.11-205.11, 2014 | 2 | 2014 |
| Synthetic chimeric antigen receptors (CARs) rapidly induce exhaustion and augmented glycolytic metabolism in human T cells and implicate persistent CD28 signaling as a driver … AH Long, RJ Orentas, CL Mackall Blood 122 (21), 192, 2013 | 2 | 2013 |
| Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients A Reschke, RM Richards, SM Smith, AH Long, LJ Marks, L Schultz, ... Frontiers in Oncology 12, 6454, 2022 | 1 | 2022 |
| 4-1BB costimulation ameliorates exhaustion and prolongs in vivo persistence of chimeric antigen receptor (CAR) expressing T cells AH Long, WM Haso, JP Smith, AJ Walker, TJ Fry, RJ Orentas, CL Mackall Cancer Research 75 (15_Supplement), 4702-4702, 2015 | 1 | 2015 |
| High strength Zr (Hf or Ti)-Ta-B ceramics IG Talmy, JA Zaykoski, AH Smith US Patent 7,854,912, 2010 | 1 | 2010 |
| Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy WN Haining, A Long, R Manguso US Patent App. 17/421,202, 2022 | | 2022 |
| Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy WN Haining, R Manguso, A Long US Patent App. 16/629,176, 2020 | | 2020 |
